Wittenbrink, Nicole
Herrmann, Sabrina
Blazquez-Navarro, Arturo
Bauer, Chris
Lindberg, Eric
Wolk, Kerstin
Sabat, Robert
Reinke, Petra
Sawitzki, Birgit
Thomusch, Oliver
Hugo, Christian
Babel, Nina
Seitz, Harald
Or-Guil, Michal
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01ZX1312)
Article History
Received: 14 November 2018
Accepted: 8 April 2019
First Online: 27 April 2019
Authors’ information
: The authors are part of the e:KID consortium, an interdisciplinary group which has as its main aim the development and establishment a systems medicine approach to personalized immunosuppressive treatment at an early stage after kidney transplantation. The consortium’s backgrounds areas include expertise in bioinformatics and machine learning (NW, ABN, CB, EL and MO), HLA antibody experimental analysis and immunology (NW, SH, KW, RS, BS, HS and MO), and the clinic of renal transplantation (PR, OT, CH and NB).
: The study was carried out in compliance with the Declaration of Helsinki and Good Clinical Practice. All participants provided written informed consent prior to inclusion into the study. The trial was approved by the Ethics Committee of the Universitätsklinikum Carl Gustav Carus Dresden. The trial is registered with ClinicalTrials.gov, number NCT00724022 (ExternalRef removed). Date of registration was July 2008 (retrospectively registered), date of enrollment was June 2008.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.